Dr. Neil Kumar, PhD., is the CEO of BridgeBio LLC, a company focused on the development of novel therapies for rare genetic disorders. Prior to that, he was a principal at Third Rock Ventures where he supported and managed various portfolio companies in addition to focusing on new company formation and due diligence. He also held the role of Vice President, Business Development and Operations for MyoKardia. Prior to joining Third Rock, Dr. Kumar was an associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s personalized medicine efforts. Before joining McKinsey, Dr. Kumar was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Dr. Kumar is the author of several peer-reviewed papers in the fields of oncology and systems biology.
Dr. Kumar holds BS and MS degrees in chemical engineering from Stanford University. He received his PhD in chemical engineering from the Massachusetts Institute of Technology.